高危人群中嗜铬细胞瘤/副神经节瘤筛查率
该回顾性研究评估了2017年1月1日至2020年6月30日某大型学术中心门诊成人高血压患者中嗜铬细胞瘤/副神经节瘤(PPGL)的筛查率与模式。203 535例高血压患者中71 088例(35%)符合至少一项纳入标准,仅2013例(2.83%)接受了PPGL筛查;肾上腺肿块合并高血压者筛查率最高(51.7%),而早发高血压和治疗抵抗性高血压者筛查率分别仅为3.9%和2.4%。
要点
- 高血压合并肾上腺肿块者PPGL筛查率为51.7%,远高于早发高血压的3.9%和治疗抵抗性高血压的2.4%。
- 接受筛查者更年轻(56.2±17.4岁 vs 64.0±17.1岁)、女性比例更高(54.1% vs 44.2%)、从不吸烟者比例更高(54.6% vs 47.5%),P均<0.001。
- 女性、黑人、肾上腺肿块、卒中、血脂异常、慢性肾脏病和阻塞性睡眠呼吸暂停与PPGL筛查几率升高相关。
核心结论
- 高血压合并肾上腺结节者约半数接受了PPGL筛查,而治疗抵抗性或早发高血压者筛查罕见。
- 与其他继发性高血压筛查类似,PPGL筛查更多在严重并发症出现后进行。
研究设计与样本
- 回顾性研究,纳入2017年1月1日至2020年6月30日某大型学术中心门诊成人高血压患者。
- 纳入标准为治疗抵抗性高血压、发病年龄<35岁的高血压和/或肾上腺肿块。
- 共识别203 535例高血压患者,其中71 088例(35%)符合至少一项纳入标准,2013例(2.83%)接受了PPGL筛查。
主要发现
- 接受筛查者较未筛查者更年轻(56.2±17.4岁 vs 64.0±17.1岁),女性比例更高(54.1% vs 44.2%),从不吸烟者比例更高(54.6% vs 47.5%),P均<0.001。
- 筛查率在高血压合并肾上腺肿块者中最高(51.7%),早发高血压者为3.9%,治疗抵抗性高血压者为2.4%。
- 多因素logistic回归显示,女性(OR 1.48,95%CI 1.34-1.63)、黑人 vs 白人(OR 1.35,95%CI 1.19-1.53)、肾上腺肿块(OR 55.1,95%CI 44.53-68.15)、卒中(OR 1.34,95%CI 1.16-1.54)、血脂异常(OR 1.41,95%CI 1.26-1.58)、慢性肾脏病(OR 1.40,95%CI 1.26-1.56)和阻塞性睡眠呼吸暂停(OR 1.96,95%CI 1.76-2.19)与PPGL筛查几率升高相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Pheochromocytomas and paragangliomas (PPGL) are rare causes of secondary hypertension, but when unrecognized, they can lead to serious complications. Data regarding PPGL screening are lacking. OBJECTIVE: This study aimed to assess the rates and patterns of PPGL screening among eligible patients. METHODS: We conducted a retrospective review of adults with hypertension seen in outpatient clinics of a large academic center between January 1, 2017, and June 30, 2020. We included patients with treatment-resistant hypertension, hypertension at age < 35 years, and/or adrenal mass(es). RESULTS: Of 203 535 patients with hypertension identified, 71 088 (35%) met ≥ 1 inclusion criteria, and 2013 (2.83%) were screened for PPGL. Patients screened were younger (56.2 ± 17.4 vs 64.0 ± 17.1 years), more often women (54.1% vs 44.2%), and never-smokers (54.6% vs 47.5%, P < 0.001 for all). The rate of screening was highest in patients with hypertension and adrenal mass(es) (51.7%, vs 3.9% in patients with early-onset hypertension, and 2.4% in those with treatment-resistant hypertension). Multivariable logistic regression showed higher odds ratio (OR) of PPGL screening in women (OR [95% CI]: 1.48 [1.34-1.63]); Black vs White patients (1.35 [1.19-1.53]); patients with adrenal mass(es) (55.1 [44.53-68.15]), stroke (1.34 [1.16-1.54]), dyslipidemia (1.41 [1.26-1.58]), chronic kidney disease (1.40 [1.26-1.56]), and obstructive sleep apnea (1.96 [1.76-2.19]). CONCLUSION: PPGL screening is pursued in roughly half of patients with adrenal nodules and hypertension, but rarely in patients with treatment-resistant or early-onset hypertension. Similar to screening for other forms of secondary hypertension, PPGL screening occurs more often after serious complications develop.
引用
- Grigoryan S, Nhan W, Zhang L, et al. Rates of Pheochromocytoma/Paraganglioma Screening in At-Risk Populations. J Clin Endocrinol Metab. 2023. PMID: 36469797. doi:10.1210/clinem/dgac701
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。